Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SPR | P35270 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158972 | 0.90 | CYP1A2 (0.48) | CYP1A2CYP2D6CYP3A4SPRTSHR | |
| SCHEMBL18030811 | 0.90 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP3A4SPRTSHR | |
| SCHEMBL18412643 | 0.84 | CYP1A2 (0.43) | CYP1A2CYP2D6CYP3A4SPRHPGD | |
| SCHEMBL13450956 | 0.83 | DNM1 (0.50) | CYP1A2CYP2D6CYP3A4SPRTSHR | |
| SCHEMBL8605559 | 0.83 | LGALS1 (0.43) | CYP1A2CYP2D6CYP3A4SPRTSHR | |
| SCHEMBL2730627 | 0.82 | SPR (0.49) | SPRTSHRHPGDHSD17B10KDM4E | |
| SCHEMBL17981826 | 0.82 | SPR (0.41) | CYP1A2CYP2D6CYP3A4SPRTSHR | |
| SCHEMBL12630106 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP3A4TSHRALDH1A1 | |
| SCHEMBL12387752 | 0.79 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP3A4ALDH1A1LMNA | |
| SCHEMBL15337843 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129350-B1 | MACROCYCLES | LUMIPHORE INC (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-2920157-B1 | DI-MACROCYCLES | LUMIPHORE INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20170183365-A1 | MACROCYCLES | LUMIPHORE, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9439984-B2 | Macrocycles | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160221971-A1 | DI-MACROCYCLES | LUMIPHORE, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20150157746-A1 | MACROCYCLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-06-11 | — | — | US | disclosed |
| US-20110189088-A1 | RADIOPHARMACEUTICAL COMPLEXES | LUMIPHORE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189088-A1 | RADIOPHARMACEUTICAL COMPLEXES | SLC39A3, SLC30A5, SLC40A1 | CYP1A2 4428/4885CYP2D6 3420/4885CYP3A4 4360/4885 |
| US-20160221971-A1 | DI-MACROCYCLES | DLD, NDC1, MCL1 | CYP1A2 1433/4885CYP2D6 396/4885CYP3A4 857/4885 |
| US-20170183365-A1 | MACROCYCLES | HCCS, ABCB7, AURKAIP1 | CYP1A2 1320/4885CYP2D6 658/4885CYP3A4 758/4885 |
| US-20150157746-A1 | MACROCYCLES | SLC39A14, SLC39A3, SLC40A1 | CYP1A2 3416/4885CYP2D6 2777/4885CYP3A4 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.